We recently published a list of Why Are These 10 Dividend Stocks Declining? In this article, we are going to take a look at ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...

Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other dividend stocks. Dividend investors have often debated the balance between high yields and ...

Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.

Pfizer Inc. (NYSE:PFE – Get Free Report) shares traded up 2.9% on Wednesday following a stronger than expected earnings report. The company traded as high as $26.69 and last traded at $26.62.

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...

US pharma giant Pfizer reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial ...

In a report released today, Elmar Kraus from DZ BANK AG maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares opened ...

US pharma giant Pfizer (NYSE: PFE) today announced that Jeffrey Legos will join the company as chief oncology officer.